Search Results for “acquisition” – Page 38 – media

UCB snags an NDA-ready epilepsy drug from Proximagen in $370M deal

UCB is beefing up its pipeline of epilepsy drugs with an NDA-ready therapy from Proximagen. The Belgian company has agreed to buy their nasal spray therapy USL261, designed as a rescue therapy for acute repetitive seizures, for $150 million in cash and another $220 million in sales and regulatory milestones.
- Source: endpts
- 578
- April 25, 2018
acute repetitive seizures Market Views Proximagen UCB
Allergan swoops in as Takeda’s third Shire bid falls short at $61B

Three of Takeda’s anticipated Shire buyout bids have already been rejected—and now, the Japanese drugmaker might just lose out to a competing bidder. Allergan, for instance, is already in talks for a buy.
- Source: fiercepharma
- 511
- April 23, 2018
drugmaker Market Views
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

Sale of Oncology business unlocks embedded value within Shire`s portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases
- Source: finance.yahoo
- 657
- April 17, 2018
Company Insights oncology rare diseases
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center.
- Source: finance.yahoo
- 628
- April 16, 2018
Clinical Trials DMD
GSK hands rare disease gene therapies over to Orchard

Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies. The deal sees GSK become an investor in Orchard, with a 19.9 percent equity stake along with a seat on the firm’s board. The UK drugs giant also stands to receive royalties and commercial milestone payments related to the acquired portfolio.
- Source: pharmatimes
- 665
- April 16, 2018
GSK Market Views rare disease gene therapies
Alexion to buy Wilson for $855m

Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. Wilson is a Swedish biopharma developing novel therapies for patients with rare copper-mediated disorders.
- Source: pharmatimes
- 476
- April 12, 2018
Alexion Market Views rare copper-mediated disorders
The top 5 mental/behavioural health startups that have raised funding

Healthcare is such a massive space, one that takes up a sixth of the entire U.S. economy, that just one small piece of that pie can be extremely lucrative. Take diabetes, for example, where there has been a slew of different companies tackling that problem, and raising money in the process, including Glooko, Omada Health, Siren and Virta Health.
- Source: VatorNews
- 1,381
- April 11, 2018
Market Views Mental health mHealth
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
- Source: Businesswire;
- 597
- April 9, 2018
acquisition CDI Market Views non-antibiotic
Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

Purchase includes Lynnwood, WA Biologics Manufacturing Facility
- Source: finance.yahoo
- 639
- April 4, 2018
acute myelogenous leukemia FDA Leukine Sanofi
Takeda moots Shire move but big questions remain

Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an approach for the company.
- Source: takeda
- 643
- April 3, 2018
Company Insights Shire Takeda

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.